THE U.S. IS in a dementia crisis. According to a recent study published in Nature Medicine, by 2060, diagnoses of cognitive decline are expected to hit a rate of 1 million a year—double what they were in 2020. That’s one of the reasons the FDA’s approval of a new test from local drug company Eli Lilly and Swiss medication company Roche is such a big deal. Developed with help from scientists at the Indiana University School of Medicine, the test, called the Elecsys pTau181, uses blood-based biomarkers to determine the likelihood that someone with dementia symptoms has Alzheimer’s disease or if they’re suffering from another disorder.

Read more HERE